<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="topic" /><meta name="keywords" content="Malaria: prophylaxis; Diethyltoluamide; DEET see Diethyltoluamide; Mefloquine: malaria: prophylaxis; Malarone: malaria prophylaxis; Chloroquine: malaria: prophylaxis; Mefloquine: malaria: prophylaxis; Proguanil; Doxycycline: malaria: prophylaxis; Malarone: malaria prophylaxis; Asplenia: malaria; Malarone: malaria prophylaxis; Mefloquine: malaria: prophylaxis; Doxycycline: malaria: prophylaxis; Chloroquine: malaria: prophylaxis; Proguanil; Mefloquine: malaria: prophylaxis; Doxycycline: malaria: prophylaxis; Malarone: malaria prophylaxis" /><meta name="IX" content="Malaria: prophylaxis; Diethyltoluamide; Mefloquine: malaria: prophylaxis; Malarone: malaria prophylaxis; Chloroquine: malaria: prophylaxis; Mefloquine: malaria: prophylaxis; Proguanil; Doxycycline: malaria: prophylaxis; Malarone: malaria prophylaxis; Asplenia: malaria; Malarone: malaria prophylaxis; Mefloquine: malaria: prophylaxis; Doxycycline: malaria: prophylaxis; Chloroquine: malaria: prophylaxis; Proguanil; Mefloquine: malaria: prophylaxis; Doxycycline: malaria: prophylaxis; Malarone: malaria prophylaxis" /><meta name="IXN" content="DEET see Diethyltoluamide" /><title>Prophylaxis against malaria: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="16019.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="16019.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=16019.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2071.htm">5 Infections</a> &gt; <a href="4012.htm">5.4 Antiprotozoal drugs</a> &gt; <a href="4013.htm">5.4.1 Antimalarials</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="16014.htm" title="Previous: Benign malarias (treatment)">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="16021.htm" title="Next: Specific recommendations">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_16019">Prophylaxis against malaria</h1><?highlighter on?><div id="pC" class="jN"><p>interactions (<a title="" href="41001i212.htm">Doxycycline</a>).</p><p>The
recommendations on prophylaxis reflect guidelines agreed by UK malaria
specialists; the advice is aimed at residents of the UK who travel
to endemic areas. The choice of drug for a particular individual should
take into account:</p><ul class="cBD"><li><p class="cQ">risk of exposure to malaria;</p></li><li><p class="cQ">extent of drug resistance;</p></li><li><p class="cQ">efficacy of the recommended drugs;</p></li><li><p class="cQ">side-effects of the drugs;</p></li><li><p class="cQ">patient-related factors (e.g. age, pregnancy, renal or
hepatic impairment, compliance with prophylactic regimen).</p></li></ul><div class="cAZ"><h2>Protection against bites</h2> <p class="cAX"><b>Prophylaxis is
not absolute</b>, and breakthrough infection can occur with any
of the drugs recommended. Personal protection against being bitten
is very important. Mosquito nets impregnated with <span>permethrin</span> provide the most effective barrier protection against insects; mats
and vaporised insecticides are also useful. Diethyltoluamide (DEET)
20–50% in lotions, sprays, or roll-on formulations is safe and effective
when applied to the skin of adults and children over 2 months of age.
It can also be used during pregnancy and breast-feeding. The duration
of protection varies according to the concentration of DEET and is
longest for DEET 50%. Long sleeves and trousers worn after dusk also
provide protection.</p></div><div id="_120555"><div class="cAZ"><h2>Length of prophylaxis</h2> <p class="cAX">In order to determine tolerance
and to establish habit, prophylaxis should generally be started one
week (preferably 2–3 weeks in the case of <span>mefloquine</span>) before
travel into an endemic area (or if not possible at earliest opportunity
up to 1 or 2 days before travel); <span class="cZ">Malarone</span>® or <span>doxycycline</span> prophylaxis should be started
1–2 days before travel. Prophylaxis should be continued for <b>4 weeks after leaving</b> (except for <span class="cZ">Malarone</span>® prophylaxis which should be stopped 1 week after leaving).</p><p>In those requiring long-term prophylaxis, <span>chloroquine</span> and proguanil may be used for periods of over 5 years. <span>Mefloquine</span> is licensed for up to 1 year (although it has
been used for up to 3 years without undue problems). <span>Doxycycline</span> can be used for up to 2 years. <span class="cZ">Malarone</span>® is licensed
for use for up to 28 days but can be used for up to 1 year (and possibly
longer) with caution. Specialist advice should be sought for long-term
prophylaxis.</p></div></div><div class="cAZ"><h2>Return from malarial region</h2> <p class="cAX">It is important to
be aware that <b>any illness</b> that occurs within 1 year
and <b>especially within 3 months of return might be malaria</b> even if all recommended precautions against malaria were taken.
Travellers should be <b>warned</b> of this and told that
if they develop any illness <b>particularly within 3 months</b> of their return they should go <b>immediately</b> to a
doctor and specifically mention their exposure to malaria.</p></div><div class="cAZ"><h2>Children</h2> <p class="cAX">Prophylactic doses are based on guidelines
agreed by UK malaria experts and may differ from advice in product
literature. Weight is a better guide than age. If in doubt telephone
centres listed under <a title="target-block: malaria advice centres" href="4012.htm#_120553">section 5.4</a>.</p></div><div class="cAZ"><h2>Epilepsy</h2> <p class="cAX"><span id="_16019.5">Both <span>chloroquine</span> and <span>mefloquine</span> are unsuitable
for malaria prophylaxis in individuals with a history of epilepsy. In areas <i>without <span>chloroquine</span> resistance</i> proguanil 200 mg daily alone is recommended;
in areas <i>with <span>chloroquine</span> resistance</i>, <span>doxycycline</span> or <span class="cZ">Malarone</span>® may be considered</span>; the metabolism of <span>doxycycline</span> may be influenced by antiepileptics (see <b>interactions:</b> Appendix 1 (<span>tetracycline</span>s)).</p></div><div class="cAZ"><h2>Asplenia</h2> <p class="cAX">Asplenic individuals (or those with severe splenic dysfunction) are
at particular risk of severe malaria. If travel to malarious areas
is unavoidable, rigorous precautions are required against contracting
the disease.</p></div><div id="_16019.8"><div class="cAZ"><h2>Renal impairment</h2> <p class="cAX">Avoidance (or dosage reduction)
of proguanil is recommended since it is excreted by the kidneys. <span class="cZ">Malarone</span>® should not be used for prophylaxis in patients with estimated glomerular
filtration rate less than 30 mL/minute/1.73 m<sup>2</sup>. <span id="_16019.6"><span>Chloroquine</span> is only partially excreted by the
kidneys and reduction of the dose for prophylaxis is not required
except in severe impairment.</span> <span>Mefloquine</span> is considered to be appropriate to use in renal impairment and does
not require dosage reduction. <span>Doxycycline</span> is
also considered to be appropriate.</p></div></div><div id="_120610"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">Travel to malarious areas should be
avoided during pregnancy; if travel is unavoidable, effective prophylaxis
must be used. <span>Chloroquine</span> and proguanil can be given in the usual doses during pregnancy, but these
drugs are not appropriate for most areas because their effectiveness
has declined, particularly in Sub-Saharan Africa; in the case of proguanil, <span>folic acid</span> 5 mg daily should be given. The centres listed under <a title="target-block: malaria advice centres" href="4012.htm#_120553">section 5.4</a> should be consulted
for advice on prophylaxis in chloroquine-resistant areas. <span id="_16019.7">Although the manufacturer
advises that mefloquine should not be used during pregnancy, particularly
in the first trimester, unless the potential benefit outweighs the
risk, studies of <span>mefloquine</span> in pregnancy (including
use in the first trimester) indicate that it can be considered for
travel to <span>chloroquine</span>-resistant areas</span>. <span>Doxycycline</span> is contra-indicated during
pregnancy. <span class="cZ">Malarone</span>® should be avoided during pregnancy unless there is no suitable
alternative.</p></div></div><div id="_16019.4"><div class="cAZ"><h2>Breast-feeding</h2> <p class="cAX">Prophylaxis is required in <b>breast-fed infants</b>; although antimalarials are present in
milk, the amounts are too variable to give reliable protection.</p></div></div><div class="cAZ"><h2>Anticoagulants</h2> <p class="cAX">Travellers taking warfarin should
begin chemoprophylaxis at least 1 week (2–3 weeks for mefloquine)
before departure. The INR should be stable before departure. It should
be measured before starting chemoprophylaxis, 7 days after starting,
and after completing the course. For prolonged stays, the INR should
be checked at regular intervals.</p></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="16014.htm">Previous: Benign malarias (treatment)</a> | <a class="top" href="16019.htm#">Top</a> | <a accesskey="]" href="16021.htm">Next: Specific recommendations</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>